Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer.

Oncotarget - 16 May 2017

Wang Zhijie, Piha-Paul Sarina, Janku Filip, Subbiah Vivek, Shi Naiyi, Gong Jing, Wathoo Chetna, Shaw Kenna, Hess Kenneth, Broaddus Russell, Naing Aung, Hong David, Tsimberidou Apostolia M, Karp Daniel, Yao James, Meric-Bernstam Funda, Fu Siqing

Abstract excerpt

PURPOSE: Genetic alterations such as activating KRAS and/or inactivating TP53 are thought to be the most common drivers to tumorigenesis. Therefore, we assessed phase I cancer patients with KRAS+/TP53+ mutations. RESULTS: Approximately 8% of patients referred to phase I clinical trials harbored concurrent KRAS and TP53 mutations. Patients who received a phase I trial therapy (n = 57) had a median OS of 12 months,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Kaplan-Meier Estimate

Share to Neoplasm Metastasis

Share to Neoplasm Staging

Share to Neovascularization, Pathologic

Share to ras Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 28430579
DOI: 10.18632/oncotarget.16840
PMCID: PMC5464912

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer.PMID 28430579Read ↗

Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies.Semantic proximity Read ↗

TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics.Semantic proximity Read ↗

Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.Semantic proximity Read ↗

PIK3CA mutation fortifies molecular determinants for immune signaling in vascular cancers.Semantic proximity Read ↗

Mutations in an Innate Immunity Pathway Are Associated with Poor Overall Survival Outcomes and Hypoxic Signaling in CancerSemantic proximity Read ↗

Transplanting normal vascular proangiogenic cells to tumor-bearing mice triggers vascular remodeling and reduces hypoxia in tumors.Semantic proximity Read ↗

VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy.Semantic proximity Read ↗

Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases.Semantic proximity Read ↗

Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts.Semantic proximity Read ↗

Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathway.Semantic proximity Read ↗

Driver gene KRAS aggravates cancer-associated stroke outcomes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.